BiotechTube
Home/Evexta Bio/Martin Olivo
MO

Martin Olivo

Chief Medical Officer

Evexta Bio

Therapeutic Areas

Oncology

Evexta Bio Pipeline

DrugIndicationPhase
Rupitasertib (DIACC3010)ER+ HER2- Advanced Breast Cancer (combination with SERD)Phase 1b (planned for 2026)
EVX020Hematologic Malignancies (as ADC payload)Discovery

Leadership Team at Evexta Bio

AC
Alain Chevallier
Chief Executive Officer
SM
Shawn M. Leland
Chairman of the Board
DB
Dominique Bridon
Chief Scientific Officer
EA
Edith A. Perez
Scientific Advisor
View full Evexta Bio profile